T cell infiltrates were increased after exposure to chemotherapy + anti-PD-1, to a stronger extent in the 4T1 model than in the MC38 model

T cell infiltrates were increased after exposure to chemotherapy + anti-PD-1, to a stronger extent in the 4T1 model than in the MC38 model. CD8+ T cells of total CD45+ cells (A), FoxP3+ CD4+ T cells of total CD45+ cells (B). Mice were treated as in Table S1. Data are shown as Mean + SEM, = 5 to 6, MannCWhitney test: * 0.05. Image_4.PDF (20K) GUID:?C37B34DD-F312-4972-B843-93C706F8FB1C Physique S5: Effect of chemotherapies, anti-PD1 or anti-PDL1 mAbs and their combination on leucocyte infiltrate subpopulations in MBT-2, 4T1, MB49, and MC38 preclinical tumor models. Flow cytometric analysis of total CD4+ T cells: CD45+CD3+CD4+ (A), CD8+ T cells CD45+ CD3+CD8+ (B),Granulocytic Myeloid Derived Suppressor Cells (G-MDSC): BI8622 CD45+ CD3- CD11b+ Ly6G+ Ly6C- (C) Monocytic Myeloid Derived Suppressor Cells (M-MDSC): CD45+ CD3- CD11b+ Ly6G- Ly6C+ (D), M1 macrophages: CD45+ CD3- CD11b+ CD68+ CD206- (E)), M2 macrophages: CD45+ CD3- CD11b+ CD68- CD206+ (F). Mice were treated as in Table S1. Data are shown as mean values+ SEM, = 5 to 6 mice/group (A), = 5 to 6 mice/group (B), = 6 Mouse monoclonal to TEC mice/group (C), = 5 mice/group (D). * 0.05 and ** 0.01 using Mann-Whitney test. Image_5.PDF (380K) GUID:?041C6356-F492-4357-AEBC-7B830C132E3B Physique S6: Effect of chemotherapies, anti-PD1 or anti-PDL1 Mabs and their combination on alternative immune checkpoints expression on CD8+ T cells in MBT-2, 4T1, MB49 and MC38 preclinical tumor models. Flow cytometric analysis of CD278 (ICOS) (A), CD223 (LAG-3) (B), CD279 (PD-1) (C), CD274 (PDL-1) (D), TIGIT (E), and TIM-3 (F) on CD8+ T cells infiltrate of CD45+ cells. Mice were treated as in Table S1. Data are shown as mean values+ SEM, = 5 to 6 mice/group (A), = 5 to 6 mice/group (B), = BI8622 6 mice/group (C), = 5 mice/group (D). Image_6.PDF (1.0M) GUID:?BC665FEB-6A9B-4292-B1F5-B0D90F1ACED6 Physique S7: Effect of chemotherapies, anti-PD1 or anti-PDL1 Mabs and their combination on alternative immune checkpoints expression on CD4+ T cells in MBT-2, 4T1, MB49, and MC38 BI8622 preclinical tumor models. Flow cytometric analysis of CD278 (ICOS) (A), CD223 (LAG-3) (B), CD279 (PD-1) (C), CD274 (PDL-1) (D), TIGIT (E) and TIM-3 (F) on CD4+ T cells infiltrate of CD45+ cells. Mice were treated as in Table S1. Data are shown as mean values+ SEM, = 5 to 6 mice/group (A), = 5 to 6 mice/group (B), = 6 mice/group (C), = 5 mice/group (D). * 0.05, ** 0.01, and *** 0.001 using Mann-Whitney test. Image_7.PDF (1003K) GUID:?71FB30ED-F282-456F-99AC-283477DDD06A Physique S8: Effect of chemotherapies, anti-PD1 or anti-PDL1 Mabs and their combination on alternative immune checkpoints expression on tumor cells in MBT-2, 4T1, MB49 and MC38 preclinical tumor models. Flow cytometric analysis of CD278 (ICOS) (A), CD223 (LAG-3) (B), CD279 BI8622 (PD-1) (C), CD274 (PDL-1) (D), TIGIT (E) and TIM-3 (F) on tumor cells infiltrate (CD45- cells). Mice were treated as in BI8622 Table S1. Data are shown as mean values+ SEM, = 5 to 6 mice/group (A), = 5 to 6 mice/group (B), = 6 mice/group (C), = 5 mice/group (D). * 0.05, ** 0.01, and *** 0.001 using Mann-Whitney test. Image_8.PDF (959K) GUID:?6C335708-AAAD-4360-BEB6-BFBDD0963A7F Table S1: experiments design overview. Data_Sheet_1.docx (19K) GUID:?C7F83229-87C4-4E17-9A02-CE469EF54711 Table S2: Flow cytometry assay design overview. Data_Sheet_1.docx (19K) GUID:?C7F83229-87C4-4E17-9A02-CE469EF54711 Table S3: Current Phase I-II clinical trials using anti-PD-1 or anti-PDL-1 in breast, colorectal and bladder cancer (from www.clinicaltrials.gov, searched items nivolumab and atezolizumab, 2018, ICI = Immune Checkpoint Inhibitor). Data_Sheet_1.docx (19K) GUID:?C7F83229-87C4-4E17-9A02-CE469EF54711 Abstract In spite of impressive response rates in multiple cancer types, immune checkpoint inhibitors (ICIs) are active in only a minority of patients. Alternative strategies currently aim to combine immunotherapies with conventional brokers.